

Resource Summary Report

Generated by [dkNET](#) on Aug 12, 2026

Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

RRID:AB_443425

Type: Antibody

Proper Citation

Abcam Cat# ab16669, RRID:AB_443425

Antibody Information

URL: http://antibodyregistry.org/AB_443425

Proper Citation: Abcam Cat# ab16669, RRID:AB_443425

Target Antigen: CD3

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry; Western Blot; Immunohistochemistry-Fr, Immunohistochemistry-P, Western Blot

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

Description: This monoclonal targets CD3

Target Organism: feline, simian, canine, baboon, horse, mouse, cat, human, dog

Clone ID: Clone SP7

Antibody ID: AB_443425

Vendor: Abcam

Catalog Number: ab16669

Record Creation Time: 20250820T042639+0000

Record Last Update: 20250820T185909+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 176 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. *Cell*, 189(4), 1039.

Belanger K, et al. (2026) Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. *Cancer research*, 86(14), 3604.

Tang R, et al. (2026) Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. *Cancer cell*.

Cheng Y, et al. (2026) A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. *Cell reports. Medicine*, 7(2), 102619.

Lin Y, et al. (2026) Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. *Cell reports. Medicine*, 7(4), 102708.

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. *Cell reports*, 45(5), 117324.

Lopez-Lago MA, et al. (2026) Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. *Med (New*

York, N.Y.), 7(7), 101149.

Al-Ghazzawi K, et al. (2026) Matched sampling reveals uncoupled phenotypic plasticity during metastasis formation in uveal melanoma. *iScience*, 29(7), 116397.

Baisiwala S, et al. (2026) A human tumor-immune organoid model of glioblastoma. *Cell reports*, 45(1), 116790.

Gerlach I, et al. (2026) Act1LR inhibition improves motor outcome and preserves muscle fibers after experimental autoimmune neuritis. *Acta neuropathologica communications*, 14(1).

Jana S, et al. (2026) Collagen-Bearing Exosomes from Breast Cancer-Associated Fibroblasts Promote T-cell Dysfunction. *Cancer research communications*, 6(3), 630.

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. *Immunity*, 59(5), 1201.

Suarez-Carmona M, et al. (2026) Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. *Signal transduction and targeted therapy*, 11(1).

Shalita R, et al. (2026) Localized PD-1 CAR T therapy reprograms neuroinflammation. *Cell*.

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. *Cell reports. Medicine*, 102932.

Pang Z, et al. (2026) Mapping cellular targets of covalent cancer drugs in the entire mammalian body. *Cell*, 189(3), 725.

Zhang Z, et al. (2026) Molecular insights into early malignant transition of hepatocellular carcinoma. *Cancer cell*, 44(5), 1012.

Allen NC, et al. (2026) NF- κ B-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K⁺ T cells. *Immunity*, 59(6), 1561.

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. *EMBO molecular medicine*, 18(5), 1967.

Sun Z, et al. (2026) Epstein-Barr Virus-Induced Upregulation of GPR183: A Potential Upstream Mechanism in IgG4-Related Ophthalmic Disease. *Investigative ophthalmology & visual science*, 67(8), 30.